Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD): Lower Revenue Guidance Highlights Concerns - Baird

July 26, 2016 6:16 AM
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but is incrementally more cautious ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles